Annovis Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard

What happened

On October 29, 2026, Annovis Bio received NYSE notice that it failed Section 802.01B because its 30-trading-day average market capitalization was below $50 million while stockholders' equity was also below $50 million.

Confirmed

Global impact / market context

Falling below both the $50 million market value and $50 million equity thresholds signals investors value the company at less than its accounting worth, which can make raising new money harder and increase pressure to cut spending or sell assets.

Analyst inference

The .BC designation flags the listing shortfall to traders while shares keep trading during the cure period, so investors can still buy and sell but face added uncertainty over whether the company regains compliance.

Analyst inference

What to watch

1. Annovis Bio plans to submit a compliance plan within 45 days of the notice, and if the NYSE accepts it, the company gets nine months from the notice to regain compliance. Confirmed
2. The shares will continue trading on the NYSE during the cure period with a .BC designation, which means the stock carries a listing-deficiency marker. Confirmed
3. Watch whether the company's average market value and stockholders' equity climb back above $50 million through share price gains, asset sales, or new financing, since falling short risks delisting. Analyst inference

Evidence

• Original source link unavailable